On September 24, Moderna, Inc. rose 3.05% in regular trading, trading at 188.005 USD/share, with turnover of $737 million, extending its recent strong momentum.

On the news front, Moderna announced that three research abstracts for its personalized mRNA cancer vaccine intismeran autogene have been accepted by the European Society for Medical Oncology (ESMO) annual meeting. The most closely watched Phase 3 INTerpath-001 trial full melanoma data is scheduled for formal release on October 24, while the remaining two abstracts will disclose clinical data on the vaccine's application in pancreatic cancer and early-stage non-small cell lung cancer. The INTerpath-001 trial, co-developed with Merck, previously delivered positive Phase 3 results, achieving both recurrence-free survival and distant metastasis-free survival endpoints — marking the world's first mRNA cancer therapy validated in a randomized Phase 3 trial.

Separately, the options market saw a $9.18 million in-the-money CALL purchase targeting a November 20 expiry at a $160 strike price, with 2,000 contracts traded, reflecting concentrated bullish positioning on further upside. Multiple institutions have recently raised price targets, with Argus Research upgrading to Buy at $180 and Berenberg lifting its target to $100.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)